Menlo Park, CA – May 15, 2013 – Auxogyn, Inc. announced today that it has been selected as a finalist for Red Herring’s Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.
Red Herring has been selecting the most exciting and promising start-ups and “scale ups” since 1995. Finalists are evaluated individually from a large pool of hundreds of candidates based across North America. Twenty major criteria underlie the scoring and process. Each company goes through an individual interview after filling out a thorough submission, complemented by a due diligence process. The list of finalists often includes the best performing and prominent companies of that year.
“The finalists list confirms the excellent choices made by entrepreneurs and VCs and the start-ups’ solid roots in corporate America, embracing their innovations. By all metrics, it emphasizes the United States’ entrepreneurial excellence,” said Alex Vieux, publisher and CEO of Red Herring.
Finalist elections for the 2013 edition of the Red Herring 100 North America award are based upon technological innovation, management strength, market size, investor record, customer acquisition and financial health. During the several months leading up to the announcement, hundreds of companies in the fields of security, Web 2.0, software, hardware, life sciences, cloud, mobile and others completed their submissions to qualify for the award.
“We are honored to be named a Top 100 finalist and be among so many distinguished companies that are on the forefront of innovation,” said Lissa Goldenstein, president and CEO of Auxogyn Inc. “Auxogyn is committed to advancing the field of reproductive health. Our goal in developing the Eeva™ Test is to help patients achieve a successful pregnancy. The availability of new innovations, such as the Eeva Test, can help IVF clinics optimize the treatment path for their patients who are undergoing IVF procedures.”
About IVF
Infertility affects one out of every eight couples in the United States. The demand for assisted reproduction tools and procedures is growing worldwide due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. This worldwide growth is occurring despite the significant cost per IVF cycle and the low success rate, with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.
About the Early Embryo Viability Assessment (Eeva) Test
The Eeva Test is designed to improve embryo selection by providing clinicians with objective information to more confidently select embryo(s) for transfer to help achieve better IVF outcomes. Eeva’s proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters discovered by researchers at Stanford University. The Eeva test not only provides novel quantitative information, but also ensures consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva’s quantitative data for each embryo’s potential development, IVF clinics may be able to optimize the treatment path for their patients undergoing IVF procedures. The effectiveness of the Eeva Test was validated in a prospective, multi-center, 54-patient clinical trial with 758 embryos. Embryologists using Eeva were significantly able to improve their ability to identify non-viable embryos relative to traditional methods. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.
Eeva is currently CE Mark approved and available for use only in the EU and is pending FDA clearance in the United States. For more information about Eeva, visit eevaivf.com or follow Eeva on Twitter @EevaIVF.
About Auxogyn
Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that IVF clinicians and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com and follow us on Twitter @Auxogyn.
Media Contact:
Jessica Volchok
BrewLife
(310) 774-3423
[email protected]